The fall COVID-19 vaccine season is starting slowly for Pfizer, with U.S. sales of its Comirnaty shots sinking 25% after ...

Pfizer (PFE) stock is in focus as the company exceeds Street forecasts with its Q3 2025 results thanks mainly to its COVID ...

Pfizer’s sales of its COVID-19 vaccine, Comirnaty, fell sharply by 25% in the U.S. during the third quarter of 2025, dropping ...

And despite the sales slump in the U.S. this past quarter, Pfizer’s Prevnar dynasty still leads in pediatric pneumococcal vaccination worldwide and among conjugated pneumococcal vaccines for adults in ...

Get the latest stock market update and key takeaways in healthcare, including Pfizer, Amgen, Novo Nordisk results, and obesity drug bidding wars.

Pfizer posts Q3 earnings beat and raises EPS guidance, but weaker COVID product sales weigh on overall revenue momentum.

Pfizer raised its 2025 profit forecast for the second time this year, as ongoing cost cuts helped make up for slow sales ...

Shares of Pfizer Inc. gave up ground in early Tuesday trading, after the drug giant reported a decline in revenue, as ...

After raising its 2025 profit forecast again, Pfizer turns its sights on Novo Nordisk in a billion-dollar obesity drug ...

Moderna lowered the top end of its 2025 revenue forecast by $200 million on Thursday, citing weaker-than-expected sales of ...

With vaccine sales on the decline, these are tough times for Merck to launch its new pneumococcal shot Capvaxive. | With ...

The fall COVID-19 vaccine season is starting slowly for Pfizer, with U.S. sales of its Comirnaty shots sinking 25% after ...